RA is characterized by chronic inflammation and a loss of immune regulation, in which the immune system attacks healthy joints, causing persistent pain and progressive damage. That combination makes it a strong fit for a therapy built to restore immune balance through regulatory T cells.
Our Focus: Rheumatoid Arthritis
A proving ground for restoring immune tolerance.
Rheumatoid arthritis is an important opportunity to demonstrate what precision regulatory T cell (Treg) therapy can do: restore immune balance in a chronic autoimmune disease, not just manage its symptoms.
Why rheumatoid arthritis?
Addressing the needs of patients with poly-refractory RA
SBT7101 is initially being developed for patients who have exhausted multiple treatment options and continue to experience active disease.
~20,000 patients in the US live with poly-refractory rheumatoid arthritis and have no standard of care options.
A Different Approach
SBT7101 integrates precision engineering with proprietary manufacturing built to preserve Treg function in inflammatory environments. By avoiding lymphodepletion and preconditioning and supporting the potential for repeat dosing, SBT7101 is designed for the realities of chronic disease.
By aligning advanced cell therapy with the long-term needs of people living with autoimmune disease, we aim to establish a new approach to restoring immune tolerance.
Regulate-RA Clinical Trial
We are conducting a Phase 1 study of our lead cell therapy candidate, SBT7101, in patients with poly-refractory rheumatoid arthritis.
For more information, please visit ClinicalTrials.gov.
